# Efficacy and Safety of AJU-C52 in Essential Hypertension Patients

> **NCT06416865** · PHASE3 · RECRUITING · sponsor: **AJU Pharm Co., Ltd.** · enrollment: 190 (estimated)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** AJU-C52L, AJU-C52
- **DRUG:** C52R1L, C52R1M

## Key facts

- **NCT ID:** NCT06416865
- **Lead sponsor:** AJU Pharm Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-27
- **Primary completion:** 2022-12-12
- **Final completion:** 2024-08-31
- **Target enrollment:** 190 (ESTIMATED)
- **Last updated:** 2024-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06416865

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06416865, "Efficacy and Safety of AJU-C52 in Essential Hypertension Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06416865. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*